Every mother-to-be who has what is considered an ‘at-risk’ pregnancy is informed of the risks to the fetus of a genetic abnormality. ‘At-risk’ can involve a long list of medical conditions (diabetes or cancer for example) or poor health choices (illegal drug use or smoking). Yet a common cause of an at-risk pregnancy is age, having a child before the age of 17 or older than 35. In the US, no less than 750,000 are considered at-risk.
“The future is already here – it’s just not very evenly distributed.” – William Gibson
This is a blog about next-generation sequencing and it’s intersection with marketing and business in general (primarily), which happens to be my particular area of professional expertise, having focused on next-generation sequencing since late 2006, when Illumina (my then-employer) acquired a startup called Solexa for $417M. I have had product development, product management, marketing (all in the San Diego area with Illumina) and key-account sales roles (in the Mid-Atlantic region of the US serving both the NIH and the entire SouthEast region with Illumina, RainDance Technologies and currently with Life Technologies). I am presently in a marketing role at Life Technologies Corporation (which used to be Applied Biosystems and Invitrogen Corporation), heavily involved with both the Ion Torrent PGM / Proton as well as the SOLiD / 5500 platforms. (More information about me can be found here; if you are interested in anything Ion Torrent and NGS market overall you’ve come to the right place.)